Lilly mAb combo gains EUA with shortened infusion time

An EUA for Lilly’s mAb cocktail to treat mild-to-moderate COVID-19 outpatients aged 12 and older comes with a shortened infusion time that could ease administration. 

FDA granted emergency use authorization to the combination of bamlanivimab and etesevimab with an infusion time of 21 minutes, and shortened the authorized infusion time for bamlanivimab monotherapy from 60 minutes to 16 minutes. ...